Cost of Illness of Japanese Patients with Chronic Lymphocytic Leukemia (CLL), and Budget Impact of the Market Introduction of Ibrutinib
Crossref DOI link: https://doi.org/10.1007/s41669-017-0024-5
Published Online: 2017-04-27
Published Print: 2017-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Mahlich, Jörg
Okamoto, Shinichiro
Tsubota, Akiko
License valid from 2017-04-27